Skip to main content
Clinical Trials/EUCTR2019-003028-19-IT
EUCTR2019-003028-19-IT
Active, not recruiting
Phase 1

Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome - PS_KSS

IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA0 sites27 target enrollmentMay 24, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Pearson and Kearns-Sayre syndrome.
Sponsor
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
Enrollment
27
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 24, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of PS/KSS syndromes with confirmed genetic mutations associated PS/KSS syndromes. Diagnosis will be performed on review of muscle/skin biopsies, presence of mtDNa deletion on mtDNA samples from peripheral blood lymphocytes, urinary tract cells in urine, or muscle (Southern blot, Long PCR, MLPA), quantification of mtDNA deletions by Quantitative PCR. If genetic confirmation and quantification of mtDNA deletion is not available, it will performed at screening
  • Newcastle Pediatric Mitochondrial Disease Scale score of \=15 and \= 60 on sections 1\-3
  • Evidence of disease progression within 12 months preceeding the screening either by NPMDS score or documented evidence of neurologic deterioration
  • Availability of pre\-enrollment brain MRI that confirms the characteristic basal ganglia damage or leukoencephalopathy of PS/KSS syndromes performed within 6 months prior to screening (if brain MRI/MRS is not available, it will performed at screening)
  • Male or female age 1 to 25 years
  • Patient or patient’s guardian able to consent and comply with protocol requirements
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 9

Exclusion Criteria

  • Allergy to folinic acid
  • Clinical history of bleeding or abnormal baseline PT, PTT (or aPTT) or INR
  • Pernicious Anemia,
  • Hereditary fructose intolerance, glucose / galactose malabsorption syndrome or sucrase\-isomaltase deficiency,
  • Not\-mitochondrial Diabetes
  • Concomitant use of methotrexate
  • Clinically significant disease, such as, but not limited to, hepatitis C virus (HCV) / human Immunodeficiency virus (HIV) / hepatitis B virus (HBV) / Cancer, that precludes study participation
  • Diagnosis of any other concurrent inborn error of metabolism
  • Previous tracheostomy
  • Ventilator dependent or use of noninvasive ventilatory support within one month of enrollment

Outcomes

Primary Outcomes

Not specified

Similar Trials